Nutri-Med Logic Corp Expands on a New Finding in Alzheimer’s, Linking Specific Nutrients to Improved Cellular Metabolic Rate

Share Article

Nutri-Med Logic Corp says that a newly published study by The School of Health Science and Healthcare Administration, University of Atlanta, Atlanta, Ga., proposes two specific nutrients for repairing and reversing the damage to nerve cells’ Mitochondria (cellular powerhouse) in Alzheimer’s patients. When taking into account the results of this study together with the results of other recent studies in Diabetic Polyneuropathy and Diabetic Retinopathy, only one of these two nutrients is becoming the key focus of attention for the brain, eyes and central nervous system.

A new study by The School of Health Science and Healthcare Administration, University of Atlanta, implicates hypometabolism (decreased cellular metabolic rate), coupled with oxidative stressors, as a central initiating factor for vascular abnormalities, mitochondrial damage and an imbalance in the activity of vasoactive (increasing or decreasing blood pressure and/or heart rate) substances.

The study proposes incorporation of specific antioxidants (nutrients) such as R-alpha lipoic acid and acetyl-L-carnitine as, seemingly, potential treatments for Alzheimer’s Disease and states “They target the factors that damage mitochondria and reverse its effect, thus eliminating the imbalance seen in energy production and restore the normal cellular function, making these antioxidants very powerful alternate strategies for the treatment of cardiovascular, cerebrovascular as well as neurodegenerative diseases including Alzheimer’s Disease.”

While this recent study refers to two nutrients, another very recent study by Kresge Eye Institute, Detroit, Michigan, only incorporated one of these two nutrients “R-Alpha Lipoic” and states: R-Alpha Lipoic “has produced a significant beneficial effect on the impaired mitochondria biogenesis (regeneration) and also on the continued progression of diabetic retinopathy.”

Moreover, another very recent study by Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, states: “Due to its properties as a potent antioxidant, alpha lipoic acid (ALA) could mitigate the development of Diabetic Sensorimotor Polyneuropathy (DSPN) and attenuate resultant symptoms and signs. Approved for treatment of DSPN in Germany, the agent is not more widely used due to uncertainty about its efficacy and reported adverse effects. Here we review the effectiveness and tolerability of ALA in the treatment of symptomatic DSPN”.

The Beth Israel Deaconess Medical Center study concluded that “Treatment with ALA 600 mg iv daily for 3 weeks represents a well-tolerated and effective therapy for DSPN. An oral dose of 600 mg daily administered for up to 5 weeks could offer benefits in symptoms and signs of DSPN without significant side effects.”

In these three studies, the common and crossing point for Diabetic Retinopathy, Diabetic Polyneuropathy and Alzheimer’s disease is the neurons (nerve cells) and R-Alpha Lipoic.

Alpha Lipoic is the shared central therapeutic nutrient for all these three studies and, in one hand, two out of the three studies solely used R-Alpha Lipoic and, on the other hand, again two of the three studies, also, proposes R-Alpha Lipoic for repair, regeneration and/or survival of cellular mitochondria (cellular powerhouse).

R-Alpha Lipoic is made and known to the human body. In the biologic processes, it is made in conjunction with the metabolism of glucose. In its reduced from, it is a vital co-enzyme.

R-Alpha Lipoic easily passes the cellular membranes and, due to its structure, in mitochondria receives a hydrogen (H) from an abundant co-enzyme “NADH” (converting it to NAD, another co-enzyme) and, as the result thereof, it becomes an potent mitochondria anti-oxidant itself. (1)

In 2007 Dr. David Sinclair, a professor of Pathology at Harvard medical School, published the result of a study, done in conjunction with National Institute on Aging, National Institutes of Health, whereas they stated Nutrient-Sensitive Mitochondrial level of NAD (a co-enzyme) Dictate Cell Survival, an important aspect as well as an important benefit in Alzheimer’s and Parkinson’s. (2)

It has been proposed that higher levels of NAD may allow the activation of Sirtuin genes, a family of genes that increase cell’s ability to resist stress and apoptosis (cell-death), extremely beneficial aspect for neurodegenerative diseases.

The mitochondrial NADH has shown a preference for R-Alpha Lipoic Acid (Lipoic Acid). In animal studies liver-cells mitochondria has shown to reduce exogenous (supplemental) Lipoic Acid.

The reduction of R-Alpha Lipoic Acid (receiving a hydrogen) from NADH would result in an increase in the cellular levels of NAD, as well as, the formation of a potent mitochondrial anti-oxidant (di-hydro-lipoic acid: the reduced form of R-Alpha Lipoic).

R-Alpha Lipoic, irrespective of its proposed ability to neutralize mitochondria superoxides, increasing the inter-cellular levels of NAD, repair and/or regeneration of mitochondria, is a key and important anti-oxidant nutrient for maintaining the healthy and normal functioning of the neurons.

In conclusion, Nutri-Med Logic Corp agrees with the all of the above studies and adds, there is a great need to further investigate the role of clinical diets, containing R-Alpha Lipoic, not only in Diabetic Retinopathy, Polyneuropathy, Alzheimer’s but all neurodegenerative diseases.

Nutri-Med Logic Corp ( is a producer of dietary supplements such as:

R-Alpha Lipoic, a potent anti-oxidant nutrient. R-Alpha Lipoic is made and known by the human body;
A Concentrated and Balanced Omega-3, a potent anti-inflammatory nutrient for the brain, eyes and the nervous system.

Nutri-Med Logic's products are Formulated Based on Nutritional Logic, made from the highest quality raw materials that are manufactured in pharmaceutical facilities, encapsulated in pharmaceutical facilities and packaged in pharmaceutical facilities.

It must be noted that the studies, sources or statements, herein, have not been evaluated by The FDA and, thus, one should not relate the cause of any diseases, stated herein, to lack of the supplements stated above; nor equate their supplementation to prevention, treatment or cure.

1. Free Radical Biology & Medicine - Elsevier. Vol 22, Issue 3, 1997, Pp 535-542.
2. Cell, Vol. 130, Issue 6, 1095-1107, 21 Sept. 2007.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

H.R. Zadeh